Blog

Real-World Data and Real-World Evidence: Advancing Clinical Pharmacology

30-09-2025

Real-World Data (RWD)—collected from electronic health records, patient registries, insurance claims, and wearable devices—provides insights into patient outcomes outside the controlled environment of clinical trials. Real-World Evidence (RWE) is generated by analyzing this data, offering actionable information on drug safety, efficacy, and effectiveness in diverse patient populations.

RWD and RWE are transforming clinical pharmacology by bridging the gap between trial results and real-life patient care. They support post-marketing surveillance, dose optimization, and risk assessment, while identifying rare adverse events that may not appear in randomized controlled trials. Integrating RWD with advanced analytics, AI, and machine learning enables predictive modeling, comparative effectiveness studies, and personalized treatment strategies.

For drug developers, regulators, and clinicians, RWD and RWE provide evidence to inform regulatory decisions, clinical guidelines, and patient-centered care. At the Global Clinical Pharmacology and Drug Development Conference, experts will explore how these insights are reshaping drug evaluation and advancing precision medicine, ensuring that therapies are both safe and effective in real-world populations.